$0.979
-0.001 (-0.07%)Zum Schluss
OSTX im Vergleich zur Peergroup
In the context of the broader market, OSTX competes directly with industry leaders such as CGTX and CSBR. With a market capitalization of $45.51M, it holds a significant position in the sector. When comparing efficiency, OSTX's gross margin of N/A stands against CGTX's N/A and CSBR's 50.54%. Such benchmarking helps identify whether OS Therapies Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von OS Therapies Inc
The company has reported continuous net losses, with Q1 2026 showing a net operating loss of $10.4 million, a 167% increase from the previous year. The gross profit remains negative, and the current ratio has dropped significantly, indicating financial distress.
Financials
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.